AGP Executive Report
Last update: 4 hours agoBiotech Breakthroughs: Praxis Precision Medicines won FDA Breakthrough Therapy designation for elsunersen in SCN2A-related seizures, while Atsena Therapeutics dosed its first Phase 3 patient in the LIGHTHOUSE trial for X-linked retinoschisis and Taysha Gene Therapies reported completion of dosing in its REVEAL pivotal Rett program. Clinical Trial Momentum: Verrica Pharmaceuticals dosed its first U.S. patient in COVE-3 for YCANTH common warts, and BrainsWay expanded Deep TMS SWIFT coverage to 57M+ covered lives. Regulatory & Access Moves: Medidata launched an Academic Site Advisory Board to reduce operational friction at research hospitals, and a Neurology® publication standardized CIDP management terms to align care and trials. Tech & Industry: Refinity secured an exclusive license from PNNL to convert olefins from waste plastics for SAF and other fuels, while Xeriant advanced NEXBOARD commercialization after Class A fire and NFPA 286 certification. AI/Policy & Global Collaboration: Malaysia and China pledged deeper STI cooperation spanning AI, biotech, green tech, and advanced materials, and G7 leaders issued a critical-minerals supply-chain declaration aimed at resilience.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
